Instructive Case
Debilitating limb pain and weakness as complications of long-term voriconazole therapy
Tristan Harding,
Corresponding Author
Tristan Harding
Department of Endocrinology, Royal Children's Hospital, Melbourne, Victoria, Australia
Correspondence: Dr Tristan Harding, Royal Children's Hospital, 10 Beckett Street, Balwyn, Melbourne, VIC 3103, Australia. Fax: +61 39417 2882; email: [email protected]
Search for more papers by this author Chris Harris,
Chris Harris
Department of Orthopaedics, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Joanne Smart,
Joanne Smart
Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Margaret Zacharin,
Margaret Zacharin
Department of Endocrinology, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author
Tristan Harding,
Corresponding Author
Tristan Harding
Department of Endocrinology, Royal Children's Hospital, Melbourne, Victoria, Australia
Correspondence: Dr Tristan Harding, Royal Children's Hospital, 10 Beckett Street, Balwyn, Melbourne, VIC 3103, Australia. Fax: +61 39417 2882; email: [email protected]
Search for more papers by this author Chris Harris,
Chris Harris
Department of Orthopaedics, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Joanne Smart,
Joanne Smart
Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author Margaret Zacharin,
Margaret Zacharin
Department of Endocrinology, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this author
First published: 08 March 2021
No abstract is available for this article.
References
- 1Hashemi H, Mohebbi M, Meharavaran S, Mazloumi M, Jahanbani-Ardakani H, Abtahi SH. Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings and treatment modalities. J. Res. Med. Sci. 2017; 22: 53.
- 2Adwan M. Voriconazole-induced periostitis: A new rheumatic disorder. Clin. Rheumatol. 2017; 16: 609–15.
- 3Barry AL, Brown SD. In vitro studies of two triazole anti-fungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 1996; 40: 1948–9.
- 4Dickinson RP, Bell AS, Hitchcock CA et al. Novel antifungal 2-aryl-1-(1H-1, 2, 4- triazol-1-yl) butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorg. Med. Chem. Lett. 1996; 6: 2031–6.
- 5Walsh TJ, Anaissie EJ, Denning DW et al.; Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 327–60.
- 6Malani A, Aronoff D. Voriconazole-induced photosensitivity. Clin. Med. Res. 2008; 6: 83–5.
- 7Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J. Am. Acad. Dermatol. 2010; 62: 31–7.
- 8Ladak K, Rubin L. Voriconazole-induced periostitis deformans: A mimicker of HPOA. Clin. Med. Res. 2017; 15: 19–20.
- 9Xing Y, Chen L, Feng Y, Zhou Y, Zhai Y, Lu J. Meta-analysis of the safety of voriconazole in definitive, empirical and prophylactic therapies for invasive fungal infections. BMC Infect. Dis. 2017; 17: 798–809.
